Mylan gains FDA nod for generic migraine therapy

05/17/2013 | Drug Store News

Mylan received federal approval for its zolmitriptan tablets in two strengths, 2.5 mg and 5 mg. The drug, which addresses acute migraine in adults, is a generic form of Zomig by IPR Pharmaceuticals.

View Full Article in:

Drug Store News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC